•						SHEE <sup>-</sup>	Γ_1_ (	DF _2_
Substitute for	form 1449A/PTO			ATTORNEY'S DK 033053-040	ст No.	APPLICATION N 09/974,768		
INIC	ODA 4 A-THOL	או טופטו	OCUBE	APPLICANT			<u> </u>	1
	7 0 1 7	N DISCL		Kenneth C. Cu FILING DATE	ındy, et	al. GROUP	<u> </u>	5
STA	ATÉMENT I	BN/APPL	LICANT	October 9, 20	01	1614	5	2 7
	FEB 1 2 200	07					ווי אורת	מדבם
	18 m. 18	*8.	U.S. PATENT DO	CUMENTS			ē	0031
	U.S. Patent D	ocument/						2 9
Examiner Initials	Number	Kind Code (if known)		tentee or Applicant ed Document	:	Date of Public (MM-DD-YY		გ ე
BB	5,352,682 ,		Sipos			10/4/94	ļ	
	5,462,933		Kramer et al.			10/31/9	5	
	5,541,348		Arya et al.			7/30/96	3	
	5,646,272		Kramer et al.			7/8/97		
	5,668,126		Kramer et al.			9/16/97	7	
BB	5,942,248 /		Barnwell			8/24/99	}	
	*	F	OREIGN PATENT	DOCUMENTS				
	Foreign Patent	Document						
Examiner Initials :	Number	Kind Code (if known)	Count	try		ate of Publication (MM-DD-YYYY)	Trans Yes	lation no
BB	0272462B1		Euro	pe		6/29/88		
	`\							
			<u> </u>					
			PATENT LITERATI			*.	,	
Examiner Initials	Include ( item (book,	name of author magazine, jour	r (in CAPITAL LETTER rnal, serial, symposium publisher, city and/o	n, catalog, etc.), d	late, page	n appropriate), title of t e(s), volume-issue numb	he per(s),	
	Adibi, S.A., "Tl	ne oligopepti				ne: Biology and Fu	action'	".
BB			pp. 332-340, <b>199</b>					,
						epatic Na <sup>+</sup> / bile action or the		NTa+ /
			J. Lipid Res., Vol.				licai i	Na /
	1		bstituted GABA a ol. <u>19</u> , pp. 149-1	-	entral r	nervous system ac	tivity:	a
	Bundgaard, H., <b>1985</b> .	in Design	of Prodrugs (Bur	ndgaard, H. Ed	1.), Else	evier Science B.V	., pp.	1-92,
1	Dieck, S.T., et a	al., "The per	ptide transporter	PepT2 is expr	essed in	n rat brain and me	diates	the
	accumulation of	f the fluores	scent dipeptide de			N <sub>E</sub> -AMCA in astro		
	GLIA, Vol., 25,							
	Ho, N. F. H., "	Utilizing bi	le acid carrier me	echanisms to e	nhance	e liver and small ir	itestin	e

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Jezyk, N., et al., "Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers", Pharm.

absorption", Ann. N. Y. Acad. Sci., Vol. 507, pp. 315-329, 1987.

Res., Vol. 16, pp. 519-526, 1999

·		SHEET _2	2_OF	_2
'Substitute for form 1449A/PTO	ATTORNEY'S DKT No. 033053-040	APPLICATION No. 09/974,768	ECH	
INFORMATION DISCLOSURE	APPLICANT Kenneth C. Cundy, et al.		CEN	
STATEMENT BY APPLICANT	FILING DATE	GROUP	Œ	

		1 October 9, 2001 1 1614 ———————————————————————————————
$\Rightarrow$		
PE	(تر ابور 100 <u>0</u>	Kagedahl, M., et al., "Use of the intestinal bile acid transporter for the uptake of cholic acid acid transporter for the uptake of cholic acid acid transporter for the uptake of cholic acid acid acid acid acid acid acid ac
RADEN	ARTO	Kim, D.C., "Evaluation of bile acid transporter in enhancing intestinal permeability of reninhibitory peptides", <i>J. Drug Targeting</i> , Vol. 1, pp. 347-359,1993.
	X	Kramer, W, et al., "Liver-specific drug targeting by coupling to bile acids", <i>J. Biol. Chem</i> Vol. 267, pp. 18598-18604, 1992.
//	-	Kramer, W., et al., "Intestinal absorption of peptides by coupling to bile acids", <i>J. Biol. Chem.</i> , Vol. <u>269</u> , pp. 10621-10627, <b>1994</b> .
	7	Kramer, W., "Bile acid derived HMG-CoA reductase inhibitors", <i>Biochim. Biophys. Acta.</i> Vol. 1227, pp. 137-154, <b>1994</b> .
		Kramer, W., et al., "Substrate specificity of the ileal and hepatic Na <sup>+</sup> / bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters", <i>J. Lipid Res.</i> , Vol. 40, pp. 1604-1617, 1999.
	)	Kullak-Ublick, G.A., et al., "Hepatobiliary transport", <i>J. Hepatology</i> , Vol. <u>32 (Suppl. 1)</u> , p
	V	Leibach, et al., "Peptide transporters in the intestine and the kidney", <i>Ann. Rev. Nutr.</i> , Vol. 16, pp. 99-119, 1996
		Mills, C.O., et al., 'Tleal absorption of tyrosine-conjugated bile acids in Wistar rats', Biochim. Biophys. Acta, Vol. <u>926</u> , pp. 154-159, <b>1987</b> .
		Navia, M.A, "Design principles for orally bioavailable drugs", <i>Drug Discovery Today</i> , Vo 1, pp. 179-189, <b>1996</b> .
	)	Petzinger, E., et al., "Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids", <i>Hepatology</i> , Vol. 22, pp. 1801-1811, 1995.
		Swaan, P.W., Use of the intestinal and hepatic bile acid transporters for drug delivery, Adv. Drug Delivery Rev, 1996, 20, pp. 59-82.
		Swaan, P.W., et al., "Enhanced transepithelial transport of peptides by conjugation to choliacid", <i>Bioconj. Chem</i> , Vol. 8, pp. 520-525, 1997.
	•	Tsuji, A., et al., "Carrier-mediated intestinal transport of drugs", <i>Pharm. Res.</i> , Vol. 13, pp. 963-977, 1996.
3 F	3	Wong, et al., "Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain", Am. J. Physiol., Vol. 275, pp. C967-C975, 1998.
<b> </b>	<u> </u>	
Exami	iner T	Date 0/1/20
	ture	Pade   Date   Considered   6/16/03